Atorvastatin plus compound probiotics in the treatment of hyperlipidemia： clinical trials

Objective To explore the efficacy of atorvastatin combined with compound probiotics in the treatment of hyperlipidemia. Methods From January 2019 to December 2019, 33 patients with hyperlipidemia were recruited from the People‘s Hospital of Inner Mongolia Autonomous Region and were randomly divided...

Full description

Saved in:
Bibliographic Details
Published inZhongguo lin chuang yan jiu Vol. 36; no. 5; pp. 675 - 678
Main Author TIAN Yingjie, WU Guang, WANG Honggui, REN Maojia, SONG Xiaopeng, CHANG Hao, GUO Zhixia, LI Xiaohong, BAI Xin, ZHAO Xingsheng
Format Journal Article
LanguageChinese
Published The Editorial Department of Chinese Journal of Clinical Research 01.05.2023
Subjects
atorvastatin
clinical trial
hyperlipidemia
probiotics
randomized
ｄouble-blind
Online AccessGet full text

Cover

More Information
Summary:Objective To explore the efficacy of atorvastatin combined with compound probiotics in the treatment of hyperlipidemia. Methods From January 2019 to December 2019, 33 patients with hyperlipidemia were recruited from the People‘s Hospital of Inner Mongolia Autonomous Region and were randomly divided into the test group（n=18） and the control group（n=15） using a randomized, double-blind, controlled trial design. The 20mg atorvastatin （once a day） plus compound probiotics（once a day, 2g each time） was given in test group, and the same dose of atorvastatin plus placebo was given in control group. The blood lipid level was measured once every 4 weeks for 12 weeks to compare the blood lipid levels at each time point between two groups. Results There were no significant differences in the baseline data between two groups (P＞0.05). There were no significant differences in the levels of TC, TG, LDL-C and other blood lipid levels related to the treatment effects between two groups(P＞0.05). At the different time points
ISSN:1674-8182
DOI:10.13429/j.cnki.cjcr.2023.05.008